Nucleai

News

Sanofi backs precision oncology firm Nucleai in $33m fundrai...

Israeli startup Nucleai has raised $33 million in a second-round financing that will be used to further its work on using artificial inte

News

AI startup Nucleai has immuno-oncology treatment failures in...

Israeli company Nucleai is putting artificial intelligence to work to discover why so many cancer patients don’t respond to immunotherapies, with the help of Swiss drugmaker De

News

Senju launches first-in-class dry eye disease drug in Japan

Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks